替格瑞洛和氯吡格雷用于急性冠脉综合征的疗效和安全性对比

Comparison of Efficacy and Safety of Ticagrelor versus Clopidogrel for Acute Coronary Syndromes

目的研究比较替格瑞洛与氯吡格雷治疗急性冠脉综合征的治疗效果以及安全性,为临床医师选择合理用药方案提供参考。方法在2016年2月-2017年4月就诊的急性冠脉综合征患者中选出158例随机分成两组(每组79例),两组患者入院后均给予常规对症治疗,对照组患者加用氯吡格雷治疗,观察组患者加用替格瑞洛治疗,对比两组患者的血小板功能、不良心血管事件发生率。结果观察组患者用药2 h、24 h、5 d时的血小板最大聚集率和平均聚集率均明显低于对照组患者,P<0.05;观察1个月期间观察组患者的不良心血管事件发生率比对照组低,且用药不良反应发生率8.86%低于对照组的20.25%,P<0.05。结论急性冠脉综合征患者应用替格瑞洛治疗疗效确切,能有效抑制血小板聚集,预防不良心血管事件发生,且用药安全性高,值得在临床上推广应用。

Objective To study and compare the efficacy and safety of Ticagrelor versus Clopidogrel for acute coronary syndromes,to provides reference for clinicians to choose rational drug use regimen. Methods A total of 158 patients who were referred to Liaoyang Center Hospital from February 2016 to April 2017 for cute coronary syndrome were randomly divided into two groups（ 79 patients in each group）. Each groups were given routine treatment after admission.The patients in control group were treated with Clopidogrel,and the experiment group were treated with Ticagrelor. To compare the platelet function and adverse cardiovascular events between two groups. Results The maximum platelet aggregation rate and the average aggregation rate of the patients in the experiment group were significantly lower than those who in the control group after 2 hours,24 hours and 5 days pharmacy（ P〈0. 05）. During 1 month,the incidence of adverse cardiovascular events in the observation group was lower than those who in control group. And also the incidence of adverse effect was 8. 86% which was lower than 20. 25% in the control group（ P〈0. 05）. Conclusions Ticagrelor is effective in the treatment of acute coronary syndrome. It can inhibit platelet aggregation and prevent the occurrence of adverse cardiovascular events effectively. Also it has high security,so it is worth to promote in clinic.